tbuckley/cabot-search huggingface dataset:
AB0645 Lymphocyte subsets t, b and nk cells in systemic sclerosis
Authors: L Schneider, V Hax, N Marcondes, RM Xavier, R Chakr
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic sclerosis (SSc) is a rare multisystem disease with underlying immune mechanisms, whose pathogenesis remains unclear. Few previous reports have evaluated lymphocyte subpopulations in SSc and your results are conflicting. <h3>Objectives</h3> The present study aimed to analyze the lymphocyte subsets in SSc patients in comparison to healthy individuals. <h3>Methods</h3> Peripheral blood (PB) samples to analyze lymphocyte subsets were obtained from a non-random convenience sample of 20 SSc patients. Twenty healthy individuals recruited from the blood bank were used as sex and age-matched controls. Blood samples were analyzed by flow cytometry for total T cells, CD4+ and CD8+ T cells subsets, CD19+ B cells and total NK cells. Statistical analyses were performed using the IBM Statistical Package for Social Sciences (SPSS 18.0). Data are expressed as mean ± SD and median and range. Non-parametric Mann–Whitney U test was used for analyses of the flow cytometry. A probability <i>p</i>&lt;0.05 was considered statistically significant. <h3>Results</h3> The mean (SD) age of SSc patients was 57.9 (14.2) years, 95% were female and 31.6% presented diffuse cutaneous SSc (dcSSc). Patients presented a lower mean total lymphocyte count compared to healthy controls (23.7% vs. 29.6%, <i>p</i>=0.026) (Table 1.). No statistically significant differences were found in the percentages or the absolute numbers of T, B or NK cells. <h3>Conclusions</h3> Our data support previous reports indicating that depletion of lymphocyte in the PB of SSc patients. However, we found no significant difference in relation to lymphocyte subtypes, which differs from the literature data. <h3>References</h3> T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review. Almeida et al, 2015. Liu M, Wu W, Sun X, Yang J, Xu J, Fu W, Li M. New insights into CD4+ T cell abnormalities in systemic sclerosis. Cytokine &amp; Growth Factor Reviews, 2016; 28:31–36. Gambichler T, Tigges C, Burkert B, Höxtermann S, Altmeyer P, Kreuter A. Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis. Eur J Med Res 2010; 15:44–46. <h3>Disclosure of Interest</h3> None declared
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy.
Authors: Giorgio V. Scagliotti, Ramaswamy Govindan, Karla Hurt, Alan Chiang
Journal: Journal of Clinical Oncology (2016)

TPS9101 Background: In the second-line setting of patients with advanced SqCLC, docetaxel is a standard of care, but the benefit provided is only modest in terms of progression free survival (PFS) while adding significant toxicity. Recent evidence from patients with advanced SqCLC who had progressed with platinum-based chemotherapy showed that use of immunotherapy was associated with longer overall survival (OS) than docetaxel. Abemaciclib is a potent and selective small molecule inhibitor of CDK 4 and 6 that appears to have single-agent activity in multiple tumor types and a manageable safety profile that is amenable to chronic administration. Patients are currently enrolling in a Phase 2 study designed to evaluate the effectiveness of abemaciclib vs docetaxel in patients with Stage IV squamous SqCLC who have relapsed after prior platinum-based therapy. Methods: Study JPBX (NCT02450539) is an ongoing randomized, open-label study evaluating treatment with abemaciclib (200 mg orally every 12 hours on Days 1 to 21 of a 21-day cycle) vs docetaxel (75 mg/m2 intravenous infusion on Day 1 of a 21-day cycle). Patients with Stage IV SqCLC patients who have progressed after platinum-based therapy are stratified at randomization according to: ECOG performance status (0 vs 1); number of prior therapies (platinum-based therapy only vs platinum-based therapy plus immune checkpoint inhibitor); and time since initiation of first-line therapy ( ≤ 9 vs > 9 months).The primary endpoint of the study is PFS; key secondary endpoints include OS and overall response rate. The study will enroll ~150 patients in 2:1 randomization (abemaciclib, 100 patients; docetaxel, 50 patients). The primary PFS analysis will be performed after 120 PFS events. By incorporating historical docetaxel data, the study has > 90% power to detect a hazard ratio (HR) of 0.64 in PFS. If the true median PFS for the docetaxel arm is 3 months, the HR of 0.64 corresponds to an approximately 1.7-month improvement in median PFS for the abemaciclib arm under an additional assumption of exponential survival distribution.The study began in August 2015; and as of 1/21/16, 48 patients have been randomized. Clinical trial information: NCT02450539.
Management of malignant pericardial effusion and tamponade
Authors: O. W. Press
Journal: JAMA (1987)

THE OPTIMAL management of neoplastic cardiac tamponade has been controversial, with ardent proponents of pericardiocentesis (with or without sclerotherapy),<sup>1-3</sup>surgical decompression,<sup>4-8</sup>and radiation therapy<sup>9-11</sup>as primary therapeutic modalities. In the eight years since this oncologic emergency was last reviewed in this journal,<sup>12</sup>several informative therapeutic trials have been reported that warrant a reappraisal of the recommended interventions for this condition. <h3>Epidemiology</h3> Although neoplastic involvement of the heart is commonly regarded as a rare condition, a compilation of autopsy series suggests that 3.4% (642/19130) of general autopsies<sup>13-18</sup>and 11.6% (1280/11078) of cancer autopsies<sup>13-21</sup>demonstrate cardiac metastatic disease. Of 770 cases of cardiac metastases for which adequate information was reported, 533 (69.2%) had involvement of the pericardium.<sup>13-16,19,21</sup>The majority of cases were clinically insignificant; however, 29% of such patients developed symptoms referable to pericardial metastases and 16% developed cardiac tamponade.<sup>22</sup>Pericardial lesions were either
JUDGE-MADE LAW.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic Analysis of the K-rev-1 Transformation-Suppressor Gene
Authors: Hitoshi Kitayama, Tomoko Matsuzaki, Yoshikazu Sugimoto, Yoji Ikawa, Makoto Noda
Journal: Environmental Health Perspectives (1991)

Flat revertants with reduced malignancy in vivo can be isolated from Kirsten sarcoma virus-transformed NIH 3T3 cells (DT line) following transfection with a normal human fibroblast cDNA expression library. We have recovered from one such revertant a 1.8-kb cDNA clone, K-rev-1, that exhibits an activity of inducing flat revertants at certain frequencies (2-5% of total transfectants) when transfected into DT cells. The K-rev-1 cDNA has the capacity to encode a protein with a calculated molecular weight of 21,000, having strong structural similarity to ras proteins (approximately 50% homology), especially in their guanosine triphosphate/guanosine diphosphate-binding, effector-binding, and membrane-attachment domains. Toward understanding the mechanism of action of K-rev-1 protein, we constructed a series of point mutants of K-rev-1 cDNA and tested their biological activities. Substitutions of the amino acid residues in the putative guanine nucleotide-binding regions (Asp17 and Asn116), in the putative effector-binding domain (residue 38), at the putative acylation site (Cys181), and at the unique Thr61 all decreased the transformation-suppressor activity. On the other hand, substitutions including Gly12 to Val12, Ala59 to Thr59, and Gln63 to Glu63 were found to significantly increase the transformation-suppressor activity of K-rev-1. These findings are consistent with the idea that K-rev-1 protein is regulated like many other G-proteins by guanine triphosphate/guanine diphosphate-exchange mechanism probably in response to certain negative growth-regulatory signals.
Benign familial chorea with onset in childhood
Authors: R. W. Chun
Journal: JAMA (1973)

Benign familial chorea, a recently recognized syndrome, is characterized by onset in childhood and by nonprogressive but persistent chorea uncomplicated by mental deterioration. The ten cases occurring in three families of the present study and others reported in the literature are the basis for our analysis of the clinical and genetic aspects of this disorder. It is clear that at least one autosomal dominant mutation is involved. It is possible that an indistinguishable clinical picture may also be caused by homozygosity for an autosomal recessive gene. Awareness of the existence of this disorder is important for the differential diagnosis of choreic states and for genetic counseling.
Editorial Board
Authors: James Field, Samuel Soskin, Beverly Hills, Garfield Duncan, Salman Azhar, Palo Alto, Hisham Barakat, George Bray, Jorge Calles-Escandon, José Caro, M Charles, George Chrousos, Bernard Bethesda, St Davis, Leslie Louis, Frederick Degroot, Mario Derubertis, Atlanta Digirolamo, William Ga, Louis Duckworth, John Elsas, Kenneth Fain, San Feingold, Andrew Francisco, New Frantz, Gregory York, Saul Freund, Henry Cleveland, New Ginsberg, Charles York, Jane Glueck, Abbas Cleveland, Fredric Kitabchi, Stanford Kraemer, Nelly Mauras, James May, Donald Mcnamara, Glenn Mortimore, Maria New, New York, Michael Pagliassotti, Ft Collins, William Pandak, Alan Richmond, Los Robinson, Stanton Angeles, Peter Segal, Richard Stacpoole, Marc Durham, John Tucson
Journal: Metabolism (2006)
The Problem of the Final M.B., B.S.Lond
Authors: None Greenwood
Journal: BMJ (1938)

<h3>SUMMARY</h3> Memory B cells (MBCs) generate rapid antibody responses upon secondary encounter with a pathogen. Here, we investigated the kinetics, avidity and cross-reactivity of serum antibodies and MBCs in 155 SARS-CoV-2 infected and vaccinated individuals over a 16-month timeframe. SARS-CoV-2-specific MBCs and serum antibodies reached steady-state titers with comparable kinetics in infected and vaccinated individuals. Whereas MBCs of infected individuals targeted both pre- and postfusion Spike (S), most vaccine-elicited MBCs were specific for prefusion S, consistent with the use of prefusion-stabilized S in mRNA vaccines. Furthermore, a large fraction of MBCs recognizing postfusion S cross-reacted with human betacoronaviruses. The avidity of MBC-derived and serum antibodies increased over time resulting in enhanced resilience to viral escape by SARS-CoV-2 variants, including Omicron BA.1 and BA.2 sub-lineages, albeit only partially for BA.4 and BA.5 sublineages. Overall, the maturation of high-affinity and broadly-reactive MBCs provides the basis for effective recall responses to future SARS-CoV-2 variants.
Association of <i>In Utero</i> Organochlorine Pesticide Exposure and Fetal Growth and Length of Gestation in an Agricultural Population
Authors: Laura Fenster, Brenda Eskenazi, Meredith Anderson, Asa Bradman, Kim Harley, Hedy Hernandez, Alan Hubbard, Dana B. Barr
Journal: Environmental Health Perspectives (2005)

From 1940 through the 1970s, organochlorine compounds were widely used as insecticides in the United States. Thereafter, their use was severely restricted after recognition of their persistence in the environment, their toxicity in animals, and their potential for endocrine disruption. Although substantial evidence exists for the fetal toxicity of organochlorines in animals, information on human reproductive effects is conflicting. We investigated whether infants' length of gestation, birth weight, and crown-heel length were associated with maternal serum levels of 11 different organochlorine pesticides: p,p -dichlorodiphenyltrichloroethane (p,p -DDT), p,p -dichlorodiphenyldichloroethylene (p,p -DDE), o,p -dichlorodiphenyltrichloroethane (o,p -DDT), hexachlorobenzene (HCB), gamma-hexachlorocyclohexane (gamma-HCCH), gamma-hexachlorocyclohexane (gamma-HCCH), dieldrin, heptachlor epoxide, oxychlordane, trans-nonachlor, and mirex. Our subjects were a birth cohort of 385 low-income Latinas living in the Salinas Valley, an agricultural community in California. We observed no adverse associations between maternal serum organochlorine levels and birth weight or crown-heel length. We found decreased length of gestation with increasing levels of lipid-adjusted HCB (adjusted gamma = -0.47 weeks; p = 0.05). We did not find reductions in gestational duration associated with any of the other organochlorine pesticides. Our finding of decreased length of gestation related to HCB does not seem to have had clinical implications for this population, given its relatively low rate of preterm delivery (6.5%).
Erratum: Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease
Authors: Miriam Merad, Petra Hoffmann, Erik Ranheim, Sarah Slaymaker, Markus G Manz, Sergio A Lira, Israel Charo, Donald N Cook, Irving L Weissman, Samuel Strober, Edgar G Engleman
Journal: Nature Medicine (2004)
The Gheel Experience
Authors: Charles D. Aring
Journal: JAMA (1974)

PROBLEMS in the wake of state mental hospital closings were touched on in a recent COMMENTARY. The release of these patients to communities not prepared to receive them has engendered anxiety, and not merely because the citizenry is unfamiliar with untoward behavior. Towns in the immediate vicinity of these hospitals have been particularly affected. The expatients seem to relish their newfound freedom, although they have been doing little besides aimlessly walking about and accordingly have been dubbed, "walkers." Besides the uneasiness they engender, it is claimed that these newly released patients are straining the public services. They are being given little care, and efforts at their rehabilitation have been desultory, to say the least. This is nothing new, but as the walls are tumbling down, the time is rather late. In light of a development that can be regarded as progressive, it may be useful to outline the experience in
THE PHILADELPHIA COUNTY MEDICAL SOCIETY.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computed tomography to evaluate chronic sinusitis
Authors: B. J. Ferguson
Journal: JAMA (1994)

<h3>In Reply.</h3> —Careful reading of our study would have revealed to Dr Jeret that separate analysis of only the epileptic cases did not result in an outcome different from those treated with carbamazepine for nonepileptic indications (top of page 769). Careful reading would have revealed to him also that there was no correlation between the daily dose per kilogram of either phenytoin or carbamazepine and global IQ (page 769). Last, careful reading would have disclosed that this study did not compare the two AEDs with each other, but rather with tightly matched controls. That "full dose" phenytoin is associated with serious neurotoxicity to fetuses is certainly concerning and should be communicated to mothers to be. Drs Loring, Meador, and Thompson believe that we should have conducted a different analysis than we have done. The essence of their complaint is that we should have compared the phenytoin and carbamazepine cohorts with
Correction to Lancet Glob Health 2015; 3 (Consortium of Universities for Global Health Abstracts special issue): S18
Journal: The Lancet Global Health (2015)

the second and third sentences of the Methods should have read: "Clinic A had an average of 18 000 patients per month and aimed to reduce waiting times in the pharmacy.Clinic B saw 13 000 patients per month and sought waiting time reductions in all departments."The Abstract was corrected on May 20, 2015.
Courage beyond science
Authors: E. G. Dimond
Journal: JAMA (1976)

THE NEW University of Missouri-Kansas City School of Medicine graduated its "charter" class in the Spring of 1976. This class represented the original group of high school graduates who entered six years earlier. From the considerable experience of these past six years, augmented by my own 32 years as a physician, surely I have learned something regarding either health, illness, education, or, remotely, wisdom. However, the more experience I have, the less I am certain that I know the message. <h3>TODAY'S MEDICINE</h3> At this point in my career, I should be accumulating a supply of useful homilies. However, the truth is that the farther I go along the path of experience, the less I seem to know for sure. It was a bit discouraging to offer this information to these new, enthusiastic medical school graduates and their proud families. In fact, it is probably anti-intellectual to admit the basic truth:
Women on Their Own
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Atrial Fibrillation
Authors: Peter Zimetbaum
Journal: Annals of Internal Medicine (2017)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. This issue provides a clinical overview of atrial fibrillation, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers.
CORRECTION
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Photodynamic therapy.
Authors: M J Manyak, A Russo, P D Smith, E Glatstein
Journal: Journal of Clinical Oncology (1988)

Photodynamic therapy (PDT) is an experimental cancer treatment modality that selectively destroys cancer cells by an interaction between absorbed light and a retained photosensitizing agent. This review discusses the basic components of photodynamic activity and examines the clinical applications of photodynamic therapy in cancer treatment. Treatment of superficial and early-stage malignancies is encouraging. Technologic advancement and further elucidation of the fundamental basis of photodynamic action should permit treatment of more advanced malignancies.